Lenvatinib (off Label)
ACC-LEN14
Eisai (investigator studies) · Phase 2 · Completed · Enrollment 26
| Arm | Reported safety |
|---|---|
| Lenvatinib 24 mg | grade 3 or higher treatment-related adverse events: 50%, primary analysis |
A count stays a count. This page does not turn a count into a percent.